Switching among antipsychotics in everyday clinical practice: Focus on ziprasidone

Postgraduate Medicine

Volumn 123, Issue 1, 2011, Pages 135-159

  Rossi, Alessandro ^a   Cañas, Fernando ^b   Fagiolini, Andrea ^c   Larmo, Ilkka ^d   Levy, Pedro ^e   Montes, José Manuel ^f   Papageorgiou, Georgios ^g   Sturlason, Runa ^h   Zink, Mathias ⁱ   Correll, Christoph U ^j,k  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b Hospital Dr Rodríguez Lafora   (Spain)

^c UNIVERSITY OF SIENA   (Italy)

^d Aurora Psychiatric Hospital   (Finland)

^e HOSPITAL DE SANTA MARIA   (Portugal)

^f Hospital del Sureste   (Spain)

^g EVANGELISMOS HOSPITAL   (Greece)

^h Mental Health Center Glostrup   (Denmark)

ⁱ CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^j ZUCKER HILLSIDE HOSPITAL   (United States)

^k ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Antipsychotic switch; Antipsychotics; Cardiometabolic; Dosing; Lipids; Metabolic; Rebound; Receptor affinity; Switching; Weight; Withdrawal; Ziprasidone

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; TIOTIXENE; ZIPRASIDONE; ZUCLOPENTHIXOL; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

AGRANULOCYTOSIS; AKATHISIA; ARTICLE; BODY WEIGHT; BODY WEIGHT DISORDER; CAREGIVER SUPPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DIABETIC KETOACIDOSIS; DOCTOR PATIENT RELATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; FAINTNESS; GALACTORRHEA; GYNECOMASTIA; HUMAN; INFORMATION RETRIEVAL; INSOMNIA; INTERPERSONAL COMMUNICATION; MEDLINE; METABOLIC PARAMETERS; NEUROLEPTIC MALIGNANT SYNDROME; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PATIENT EDUCATION; PATIENT IDENTIFICATION; PSYCHIATRIST; QT INTERVAL; QT PROLONGATION; REBOUND; RECOMMENDED DRUG DOSE; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; WEIGHT GAIN; WEIGHT REDUCTION;

ANTIPSYCHOTIC AGENTS; DRUG SUBSTITUTION; HUMANS; PATIENT EDUCATION AS TOPIC; PIPERAZINES; SCHIZOPHRENIA; THIAZOLES;

EID: 79952802184     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.01.2255     Document Type: Article

References (59)

1. Weiden PJ, Young AH, Buckley PF. The art and science of switching of antipsychotic medications, part 1. J Clin Psychiatry. 2006;67(11):e15.
2. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
3. Stroup TS, Lieberman JA, McEvoy JP, et al; CATIE Investigators. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163(4): 611-622.
4. Correll CU. Real-life switching strategies with second-generation antipsychotics. J Clin Psychiatry. 2006;67(1):160-161.
5. Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry. 2007;68(suppl 4):34-39.
6. Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry. 2007;68(suppl 6):10-13.
7. Scheifler PL, Weiden PJ. Beyond psychopharmacology. Psychosocial strategies for getting the best results when switching antipsychotic medications. Postgrad Med. 2006;Spec No:45-53.
8. Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25(suppl 2):S12-S21.
9. Fagiolini A, Cañas F, Gallhofer B, et al. Strategies for successful clinical management of schizophrenia with ziprasidone. Expert Opin Pharmacother. 2010;11(13):2199-2220.
10. Edlinger M, Baumgartner S, Eltanaihi-Furtmüller N, Hummer M, Fleischhacker. Switching between second-generation antipsychotics: why and how? CNS Drugs. 2005;19(1):27-42.
11. Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003;64(5):580-588.
12. Simpson GM, O'Gorman CJ, Loebel A, Yang R. Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia. CNS Spectr. 2008;13(10):898-905.
13. Alptekin K, Hafez J, Brook S, et al. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol. 2009;24(5):229-238.
14. Rossi A, Vita A, Tiradritti P, Romeo F. Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. Int Clin Psychopharmacol. 2008;23(4):216-222.
15. Stip E, Zhornitsky S, Potvin S, Tourjman V. Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(6):997-1000.
16. Kim SW, Shin IS, Kim JM, Bae KY, Yang SJ, Yoon JS. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clin Neuropharmacol. 2010;33(3):121-125.
17. Lublin H, Haug HJ, Koponen H, Sigmundsson T, Kolb SA. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. World J Biol Psychiatry. 2009:10(4 pt 3):710-718.
18. Montes JM, Rodriguez JL, Balbo E, et al. Improvement in antipsychoticrelated metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):383-388.
19. Bartkó G, Trixler M, Bitter I, Degrell I, Füredi J, Faludi G; Ziprasidonra Váltást Vizsgáló Munkacsoport. Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics [in Hungarian]. Neuropsychopharmacol Hung. 2006;8(4): 201-209.
20. Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23(6):595-600.
21. Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE. Longterm changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology. 2008;33(5):985-994.
22. Buckley PF, Harvey PD, Bowie CR, Loebel A. The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophr Res. 2007;94(1-3):99-106.
23. Loebel A, Siu C, Romano S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr. 2004;9(5):357-364.
24. Harvey PD, Meltzer H, Simpson GM, Potkin SG, Loebel A, Siu C, Romano SJ. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res. 2004;66(2-3): 101-113.
25. Grootens KP, van Veelen NM, Sitskoorn MM, et al. Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia. Eur Neuropsychopharmacol. 2010;20(12):907-912.
26. Garman PM, Ried LD, Bengtson MA, Hsu C, McConkey JR. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia. J Am Pharm Assoc (2003). 2007;47(3):373-378.
27. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
28. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
29. National Institute of Mental Health. Clinical Global Impression (CGI). In: Guy W, ed. ECDEU assessment manual in psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1970:217-222.
30. Chouinard G, Ross-Chouinard A, Annable L, et al. The extrapyramidal symptom rating scale. Can J Neurol Sci. 1980;7:233.
31. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
32. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. 1970;212(suppl):11-19.
33. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health Education and Welfare Publication (ADM) 76-338. Rockville, MD: National Institute for Mental Health; 1976.
34. IMS Health Inc. International Medical Systems National Disease and Therapeutic Index. Plymouth Meeting, PA: IMS Health; January 2001-December 2004.
35. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64(suppl 19):6-12.
36. Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl). 2004;174(4):477-489.
37. Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry. 2007;68(suppl 4):34-39.
38. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry. 2008;69(suppl 1):4-17.
39. Capsule. Summary of product characteristics. Pfizer AB, 191 90 Sollentuna, Sweden. Revised September 4, 2009.
40. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24(2):192-208.
41. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167(6):686-693.
42. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 2010;67(3):255-262.
43. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663-667.
44. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int J Psychopharmacol. 1995;10(suppl 3):S133-S138.
45. Reitan R. Validity of the Trial Making Test as an indicator of organic brain disease. Percept Psychomotor Skills. 1958;8:271-276.
46. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
47. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Press, Inc; 1994
48. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993;163;(22):39-44.
49. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
50. Geodon capsules and injections for intramuscular use [package insert]. LAB-0273-16.0. New York, NY: Pfizer Inc. Revised November 2009. http://media.pfizer.com/files/products/uspi_geodon.pdf. Accessed September 24, 2010.
51. Strom BL, Eng SM, Faich G, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The ziprasidone observational study of cardiac outcomes (ZODIAC) [published online ahead of print November 1, 2010]. Am J Psychiatry.
52. Citrome L. Using oral ziprasidone effectively: the food effect and doseresponse. Adv Ther. 2009;26(8):739-748.
53. Gandelman K, Alderman JA, Glue P, et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J Clin Psychiatry. 2009;70(1):58-62.
54. Bowden CL. Treatment strategies for bipolar depression. J Clin Psychiatry. 2010;71(5):e10.
55. Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications. J Clin Psychiatry. 2007;68(suppl 6):14-23.
56. Zyprexa [package insert]. ZY49M. Indianapolis, IN: Eli Lilly and Co. Updated January 15, 2010. http://pi.lilly.com/us/zyprexa-pi.pdf. Accessed September 24, 2010.
57. Hudson TJ, Owen RR, Thrush CR, Han X, Pyne JM, Thapa P, Sullivan G. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry. 2004;65(2):211-216.
58. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L; MOZART Study Group. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res. 2009;113(1):112-121.
59. Erratum in: Schizophr Res. 2010;121(1-3):281.